Director Homcy reduces stake to 916,674 BBIO shares after planned sales

Rhea-AI Filing Summary

BridgeBio Pharma director Charles J. Homcy executed pre-planned stock sales under a Rule 10b5-1 plan, selling a total of 300,000 shares of BBIO across transactions dated 08/08/2025 and 08/11/2025. The filings show sales of 191,662 shares at a weighted average price near $45.87, 58,338 shares at a weighted average near $46.64, and 50,000 shares at $48, leaving the reporting person with 916,674 shares following the final sale.

The disclosure notes the transactions were effected under a 10b5-1 plan adopted May 8, 2025, and the reporter remains a significant holder with well over nine hundred thousand shares. All sales are reported as direct holdings without derivative activity disclosed.

Insights

Corporate Governance Expert

TL;DR: Routine, pre-arranged insider sales under a 10b5-1 plan; not an unusual governance event.

The transactions were made pursuant to a Rule 10b5-1 sales plan, which typically indicates pre-scheduled disposals rather than opportunistic insider trades. Reporting shows the director sold 300,000 shares in three tranches and still holds 916,674 shares directly, suggesting continued alignment with shareholders. No derivatives or unusual transfer mechanisms are disclosed. From a governance standpoint this is a standard disclosure that reduces informational asymmetry but warrants monitoring if similar patterns continue.

Securities Analyst

TL;DR: Material by size but likely neutral for valuation; sales follow an announced trading plan.

The reported sales total 300,000 shares executed at weighted averages reported around $45.87, $46.64, and $48. While the absolute number is meaningful, the use of a pre-established 10b5-1 plan lowers the likelihood these sales signal new, material private information. The filings show no exercised options or other derivatives, and remaining direct ownership remains above 900,000 shares, maintaining significant insider exposure to company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOMCY CHARLES J

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/08/2025		S(1)		191,662	D	$45.8703(2)	1,025,012	D
Common Stock	08/08/2025		S(1)		58,338	D	$46.6394(3)	966,674	D
Common Stock	08/11/2025		S(1)		50,000	D	$48	916,674	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025.

2. Represents the weighted average sale price of the shares sold from $45.395 to $46.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $46.40 to $46.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BridgeBio (BBIO) insider Charles Homcy sell?

He sold a total of 300,000 shares of BridgeBio common stock in three transactions reported on 08/08/2025 and 08/11/2025.

At what prices were the BBIO shares sold?

Weighted average prices reported are approximately $45.87 for the largest tranche, $46.64 for the second tranche, and $48.00 for the final tranche.

Were these sales part of a trading plan?

Yes. The Form 4 states the transactions were effected pursuant to a Rule 10b5-1 sales plan adopted May 8, 2025.

How many BBIO shares does the reporting person hold after the sales?

916,674 shares are reported as beneficially owned directly following the final reported sale.

Did the Form 4 report any derivative activity?

No. Table II contains no entries; the disclosure covers only non-derivative common stock sales.